

Original Research Article

Determining factors for Cannabis use among Moroccan Schizophrenic Patients: A cross sectional study

Sara Bouri¹, Hanane Zemmama³, Khadija El Ayoubi Idrissi³, Mohamed Amine Berraho⁴, Abdelfattah Abdellaoui¹, Lyoussi Badiaa^{1,*}, Ismail Rammouz³, Sanae Achour²

¹Department of Biology, Sidi Mohamed Ben Abdellah University, Laboratory of Physiology-Pharmacology & environmental Health, Faculty of Science Fez, BP 1796 Fez-Atlas 30003, Morocco

²Department of Toxicology, University Hospital Hassan II Fez, BP 1893, road of Sidi Hrazem Fez 30000, Morocco

³Department of Psychiatry, University Hospital Hassan II Fez, BP 1893, road of Sidi Hrazem Fez 30000, Morocco

⁴Department of Epidemiology Public Health Pathway, Faculty of Medicine Fez, BP 1893, road of Sidi Hrazem Fez 30000, Morocco

Article history:

Received: Oct 06, 2018

Received in revised form:

Jul 05, 2019

Accepted: Jul 23, 2019

Vol. 10, No. 1, Jan-Feb 2020,
89-100.

*** Corresponding Author:**

Tel: 0661354246

lyoussi@gmail.com

Keywords:

Cannabis

Schizophrenia

Toxicological analysis

Prevalence

Comorbidity

Abstract

Objective: Cannabis use is considered a major clinical problem associated with a poorer outcome in patients with schizophrenia. The objective of the present study was to assess the prevalence of cannabis use among patients with schizophrenia. The assessment consists in comparing some factors related to substance use in a population of schizophrenic patients between cannabis users and non-

Materials and Methods: Four hundred and three participants who were examined prospectively during their hospitalization answered the PANNS scale of schizophrenia, GAF, BIS-10, CDSS, and MARS. The consumption of cannabis was investigated using urine toxicological analysis. Sociodemographic, clinical and therapeutic data were also recorded.

Results: The prevalence of cannabis use among schizophrenic inpatients was 49%. Patients with cannabis use were younger (31.7 vs 34.9 years old, $p < 0.001$), more often male (52 vs 20% female, $p < 0.001$), and they presented more often a history of imprisonment (68.8% vs 31.2%, $p < 0.001$). Patients who were users of cannabis had a lower age at onset of the disease than non-users (23.6 vs 24.8 years, $p = 0.029$), and more often with poor medication adherence ($p = 0.001$). Logistic regression revealed that factors associated with cannabis use among schizophrenics were the age, gender, history of imprisonment and poor medication adherence.

Conclusion: The study showed that a high prevalence of cannabis use among patients with schizophrenia which was associated with negative overall outcomes. Determining comorbid substance use disorders among schizophrenic patients is crucial as it may contribute to establish a better therapeutic strategy.

Please cite this paper as:

Bouri S, Zemmama H, El Ayoubi Idrissi K, Berraho MA, Abdellaoui A, Badiaa L, Rammouz I, Achour S. Determining factors for cannabis use among Moroccan schizophrenic patients: A cross sectional study. Avicenna J Phytomed, 2020; 10(1): 89-100.

Introduction

Cannabis is considered the most widely used illicit substance around the world (Degenhardt *et al.*, 2013). The use of this substance could significantly increase the risk of development of a psychotic disorder, specifically among people who used it at an early age (Large *et al.*, 2011; Donoghue *et al.*, 2014; Helle *et al.*, 2016), usually used high-potency cannabis (Di Forti *et al.*, 2014; Marconi *et al.*, 2016) and have a high genetic vulnerability for psychosis (Di Forti *et al.*, 2012; Caspi *et al.*, 2005; Mustonen *et al.*, 2018). People with schizophrenia are more likely to use cannabis than the general population (Koskinen *et al.*, 2010). The results from meta-analysis of 35 studies from 16 countries revealed a median lifetime rate of cannabis use disorders of 27.1% compared with the general population (8%) (Koskinen *et al.*, 2010). The use of cannabis is mostly associated with treatment-resistant forms of schizophrenia (Foti *et al.*, 2010), severe positive symptoms (Foti *et al.*, 2010; Large *et al.*, 2014; Seddon *et al.*, 2016), poor engagement with services and increased rates of relapse and hospitalization (Volkow, 2009; Schoeler *et al.*, 2016), higher rate of violence (Dugré *et al.*, 2017), and poor medication adherence (Foglia *et al.*, 2017). Cannabis use could be a form of self-medication in order to reduce symptoms or side effects of the antipsychotic medications (Van Dij *et al.*, 2012).

Previous epidemiological studies have reported high rates of cannabis use and cannabis use disorders among people with mental illnesses. Population-based data collected in the early 1980s by the Epidemiologic Catchment Area (ECA) study, revealed that around 50% of individuals with DSM-III psychiatric disorders meet criteria for lifetime diagnosis of cannabis use disorders (Reiger *et al.*, 1990). In Morocco, a study carried out among 108 patients with schizophrenia, found that cannabis is the most commonly used illicit substance by patients after tobacco, with a life prevalence rate of 60% (El ghazouani *et al.*, 2015). Most of the

studies rely mainly on the patients' self-reports regardless of the problems related to the under-report of their drug use (Carey *et al.*, 2003; Carey and Correia, 1998; Kilpatrick *et al.*, 2000) and there has been little evaluation of the reliability of substance use reported for patients with schizophrenia or other serious mental illnesses (Møller and Linaker, 2010). The use of biological methods tends to improve the detection of substance use over self-report assessment (de Beaufort *et al.*, 2007; Bessa *et al.*, 2010; Mieczkowski, 2010). Therefore, determining comorbid substance use disorders among patients with schizophrenia is crucial as it may contribute to establish a better therapeutic strategy.

To date, there are no studies based on the biological assessment to confirm substance use among psychotic populations in Morocco. Most of the available studies evaluating comorbidities addictions/schizophrenic disorders were conducted in North America and Europe, and few of them were carried out in other parts of the world, especially in cannabis producing countries such as Morocco.

The present study aimed to evaluate the prevalence of cannabis use among schizophrenic patients using biological assessments, determine the risk factors associated with this consumption, and compare the socio-demographic, clinical and therapeutic characteristics between cannabis users and non-users.

Materials and Methods

Participants and design

The current study was conducted in the Psychiatric Hospital Center Ibn Hassan at Fez, Morocco in collaboration with the toxicology laboratory of CHU Hassan II Fez, over a period of 14 months between May 2013 and July 2014.

The inclusion criteria for this study were: the patients must be hospitalized, with ages from 18 and 65 years, accept to participate by giving an informed consent, meet the DSM-IV-R criteria for

Determining factors for cannabis use in schizophrenia

schizophrenia, and be recorded as schizophrenics 2 years prior the beginning of the study. Patients that were excluded from the study were: non-consenting and non-cooperative patients, patients with neurological disorders and/or psychiatric comorbidity other than depression, and/or patients who were hospitalized two or more times during the period of the study. Based on the aforementioned criteria, from a total number of 512 participants (high number of patients was due to the fact that the Psychiatric Hospital Center Ibn Hassan at fez is the only Psychiatric hospital that covers the needs of a large region), 403 patients fulfilled the criteria of the inclusion and 109 schizophrenic patients were excluded because they met one of the exclusion criteria.

The participants who met the criteria of the study were interviewed by a qualified psychiatrist or a staff member. The data were collected through a special survey document completed from: the interview with the patients, collateral information, family members, and by checking their medical records. The participants provided their informed consent after fully understanding the study. Then, they were assessed after improvement of the acute schizophrenia symptoms, and just before their discharge from the hospital.

Sociodemographic data included gender, age, marital status, living situation, employment and socioeconomic-status. These variables were coded dichotomously while education was measured categorically (never schooled, primary, and secondary). Clinical data included age of onset of schizophrenia, number of hospitalizations and the type of schizophrenia, while therapeutic data contained only antipsychotic treatment. A list of cannabis use was provided to determine the prevalence and the quantity of cannabis use, and a urinary drug screening was performed for all the participants. After urine analysis, participants underwent baseline assessment.

Instruments

Cannabis Use

The rate of use (frequency of cannabis use) and average consumption (in grams) were assessed for a period of 3 months before the interview. The use of cannabis was evaluated using: self-report (patients' self-reports), and collateral report (family members reporting the cannabis use of the patients during the previous months). Schizophrenic patients were also subject to urine toxicological analysis for cannabis (Δ^9 -tetrahydrocannabinol). This analysis was carried out on a fresh urine sample that was collected from patients one day after hospitalization. Drug urine analysis was performed using both a rapid multiple immunoassay urine drug test cassette with a detection threshold 50 ng/l and ELISA test (OLYMPUS analyzer) with a threshold of 25 ng/l.

Clinical assessments

All the schizophrenic patients were assessed by a trained psychiatrist using the following psychometric scales to assess the psychiatric disorders: The Positive and Negative Syndrome Scales (PANSS) (Kay et al., 1987) were used to assess positive, negative, and general psychopathology symptoms. Global functioning was assessed using the Global Assessment of Functioning Scale (GAF) (American Psychiatric Association, 2003). Impulsivity was assessed using the Barratt Impulsiveness Scale (BIS-10) (Patton et al., 1995). Depression was assessed using the Calgary Depression Scale for Schizophrenia (CDSS) (Ddington et al., 1993), and medication adherence assessment was done based on Medication Adherence Rating Scale (MARS) (Thompson et al., 2000).

Statistical analysis

Data were analyzed using SPSS software version 21 (Statistical Package for Social Sciences). Descriptive statistical analyses were conducted for patients' demographic and clinic information. The

chi-square test was used to compare the socio-demographic, therapeutic and clinical characteristics of patient's users and non-users of cannabis. For the categorical variables, the t test was used to compare the means of quantitative data. Multivariate analysis was performed to identify factors associated with cannabis use. Odds ratio (OR) and 95% confidence interval (95% CI) were calculated. A p value of < 0.05 was accepted as statistically significant.

Results

Participants

From the 403 patients who have enrolled, 90% were men. The mean age was 33.3 years (± 9.1 years). Most patients were single (76.2%), and unemployed (72.7%) and had a low socio-economic status (88.1%). A percentage of patients (45.3%) had a secondary level of education. Most of the patients included in this study had the diagnosis of paranoid schizophrenia (62%), followed by disorganized schizophrenia (19.1%). The average age of onset was 24.24 ± 5.7 years and the average number of hospitalizations was 4.5 ± 4.7 . The average length of inpatient stay was 13.44 ± 7.20 days. Therapeutically, the majority of hospitalized schizophrenic patients had received typical antipsychotic monotherapy (89.3%).

Cannabis use

From 403 patients who were screened in this study, 198 (49%) were positive for THC. The average age of onset of cannabis use, was 18.85 ± 4.65 with an age range of 10 to 39 years. As expected, cannabis use was much more frequent among males (52.3 vs. 20% female). The percentage of patients who used cannabis regularly was 39.4% and 20.2% of them had used it occasionally.

Comparison of cannabis users and non-users

Table 1 shows the comparison of users and non-users of cannabis, based on the socio-demographic, clinical and treatment characteristics. Regarding socio-demographic characteristics, there was a significant difference in terms of the age, gender, marital status, and history of imprisonment between the two groups. Patients with cannabis use were younger (31.7 vs 34.9 years, $p < 0.001$), and usually male (52 vs 20% female, $p < 0.001$), and they presented more often a history of imprisonment (68.8 vs 31.2%, $p < 0.001$). Table 2 shows that users of cannabis had lower ages at the onset of the disease compared to the non-users (23.6 vs 24.8 years, $p = 0.029$), and more often showed medication non-adherence ($p = 0.001$). We did not notice any difference between the users and non-users of cannabis in terms of the type of schizophrenia, number of hospitalization, and the type of medication use.

Table 2 shows the correlation between the psychometric scales and cannabis use among schizophrenic patients. Cannabis using patients had significantly higher scores for BIS-10 (impulsiveness) total score than non-using patients (65.8 vs 63.9; $p = 0.01$). Besides, we found a significant correlation between medication adherence (MARS) and cannabis use among schizophrenic patients. An important significant frequency of medication adherence (76%) among cannabis non-users (76 vs 24%, $p = 0.009$) was demonstrated. Regarding the symptoms of schizophrenia (assessed by PANSS), depression symptoms (evaluated by the CDSS), and the global functioning (GAF), the results showed no correlation between these parameters and the use of cannabis.

Determining factors for cannabis use in schizophrenia

Table 1. Comparison of schizophrenic patients with and without cannabis consumption: socio-demographic characteristics

Variables	All patients (N=403) N(%)	non users (N=205) N(%)	users of cannabis (N=198) N(%)	p
Age (mean, SD)	33.35±9.16	34.93±9.47	31.71±8.54	0,000
Sex				
Male	363 (90.1)	173 (47.7)	190 (52.3)	0,000
Female	40 (9.9)	32 (80.0)	8 (20.0)	
Marital status				
Single	307 (76.2)	146 (47.6)	161 (52.4)	0,043
Married	62 (15.4)	40 (64.5)	22 (35.5)	
Divorced	34 (8.4)	19 (55.9)	15 (44.1)	
Children				
No children	340 (84.4)	167 (49.1)	173 (50.9)	0,102
Have children	63 (15.6)	38 (60.3)	25 (39.7)	
Living situation				
Alone	341 (84.6)	179 (52.5)	162 (47.5)	0,126
With family	62 (15.4)	26 (41.9)	36 (58.1)	
Education				
Never schooled	56 (13.9)	34 (60.7)	22 (39.3)	0,262
Primary	164 (40.8)	82(50.0)	82 (50.0)	
Secondary	182 (45.3)	88 (48.4)	94 (51.6)	
Occupation				
Unemployed	293 (72.7)	148 (50.5)	154 (49.5)	0,815
Employed	109 (27.2)	57 (51.8)	53 (48.2)	
Socioeconomicstatus				
Lower	355 (88.1)	182 (51.3)	173 (48.7)	0,760
Middle &higher	48 (11.9)	23 (47.9)	25 (52.1)	
Environment				
Rural	309 (77.4)	163 (52.8)	146 (47.2)	0,229
Urban	90 (22.6)	41 (45.6)	49 (54.4)	
History of imprisonment				
No	309 (76.6)	175(56.6)	134 (43.4)	0,000
Yes	93 (23.1)	29 (31.2)	64 (68.8)	

Logistic regression

Logistic regression (Table 3) shows that the factors that were significantly associated with the risk of cannabis use were age (OR 0.96, CI 0, 93-0, 98, p=0.001), protective risk factors included

female sex (OR 0.32, CI 0, 14-0, 73, p=0.007), history of imprisonment (OR 2.63, CI 1, 57-4, 39, p=0.001), and medication non-adherence (OR 5.27, CI 1, 70-16, 23, p=0.001).

Table 2. Comparison of schizophrenic patients with and without cannabis consumption: clinical and therapeutic characteristics

Variables	non users(N=205)	users of cannabis (N=198)	p
	N (%)	N (%)	
Type of schizophrenia			
Paranoid	118(47.2)	132 (52.8)	0.189
Disorganized	39 (50.6)	38 (49.4)	
Residual	4 (57.1)	3 (42.9)	
Undifferentiated	12 (66.7)	6 (33.3)	
Schizo-affective	32 (62.7)	19 (37.3)	
Antipsychotic treatment			
Typical antipsychotics	177 (49.6)	180 (50.4)	0.102
Atypical antipsychotics	27 (62.8)	16 (37.3)	
Treatment dropout			
No	21 (84.0)	4 (16.0)	0.001
Yes	183 (48.8)	122(51.2)	
CDSS (depression)			
No	183 (50.1)	182 (49.9)	0.363
Yes	22 (57.9)	16 (42.1)	
MARS (adherence)			
No	186 (49.2)	192 (50.8)	0.009
Yes	19 (76.0)	6 (24.0)	
Age of onset of schizophrenia (mean±SD)	24.84±5.98	23.60±5.34	0.029
Duration of psychotic illness(mean±SD)	10.14±7.70	8.10±6.44	0.004
Number of hospitalization (mean±SD)	4.92±5.22	4.14±4.08	0.096
PANSS Total (mean±SD)	59.01±11.48	59.33±10.60	0.769
PANSS Positive (mean±SD)	20.15±5.35	20.19±4.92	0.944
PANSS Negative (mean±SD)	15.23±5.35	16.10±5.63	0.128
PANSS Psychopathology (mean±SD)	23.61±5.73	23.04±10.60	0.292
GAF (general functioning) (mean±SD)	25.46±5.73	24.48±5.44	0.790
BIS-10 (impulsivity) (mean ±SD)	63.96±6.13	65.85±6.29	0.002

Table 3. Logistic regression assessing factors associated with cannabis consumption

Variable	Odd ratio adjusted	95% CI	p
Age(for 1 year)	0,96	0,93-0,98	0,001
Sex			
Male	1	-	0,007
Female	0,32	0,14-0,73	
History of imprisonment			
No	1	-	0,001
Yes	2,63	1,57-4,39	
Non-adherence			
No	1	-	0,004
Yes	5,27	1,70-16,23	

Discussion

To the best of our knowledge, this is the first study that was conducted in Morocco to evaluate the prevalence of cannabis use among schizophrenic patients using toxicological analysis. This approach aims to confirm cannabis use based on toxicological analysis the patients' self-reports about the cannabis use and to increase the reliability of the study. The main result of this study was that 49% of the schizophrenic patients use cannabis. This prevalence is in a good agreement with data reported by Green et al. (2005), in which they found a mean of 42.2% lifetime prevalence of cannabis use within 53 treatment samples (53 Studies included in the analyses of clinical data). This high prevalence among schizophrenic patients can be interpreted in two ways: on one hand, schizophrenia and cannabis use reinforce each other. On the other hand, cannabis use improves the well-being of the patients by managing their stress, improving their social interactions, reinforcing their control of psychotic symptoms, and reducing the side-effects of the antipsychotic treatment.

Some differences in terms of sociodemographic characteristics and clinical outcomes were found between the schizophrenic patients; users and non-users of cannabis. The multivariate analysis showed that genders, age, history of imprisonment and medication non-adherence are associated with the use of cannabis among the patients with schizophrenia.

Socio-demographic and clinical characteristics

The analysis of the results showed that the patients with cannabis use are young, and predominantly male, and had a lower age at the onset of the disease (schizophrenia). These characteristics are consistent with the findings reported by the previous studies (Compton et al., 2009; Large et al., 2011; Di Forti et al., 2014). The parameter of lower age at the onset of

schizophrenia could be interpreted in two different ways: either cannabis use triggers the symptoms of schizophrenia for the individuals who have a genetic predisposition of the disease; or the early onset of symptoms leads the patients to use cannabis as a self-medication to cope with their disease (Hambrecht and Hafner, 1996; Degenhardt et al., 2003). The hypothesis of self-medication has not been widely supported by the previous studies done in the regard (Henquet et al., 2005a; Henquet et al., 2005b)

The multivariate analysis showed that male schizophrenic patients present higher odds of cannabis use compared to female patients. So, the gender of the patient is a risk factor for male and a protective factor for female. These findings are in a good agreement with those shown by previous studies where male gender and youth (age of the patient) are risk factors for substance abuse (Cantor-Graae et al., 2001; Jimenez-Castro et al., 2010). The results of the present study also showed that the history of imprisonment is another risk factor that could increase the vulnerability to use cannabis among schizophrenic patients. These findings are consistent with those from other studies which showed that the risk of criminality among schizophrenic patients with substance use is high (Schanda et al., 2010). A longitudinal study conducted in a sample of 1353 Norwegians, aged from 13 to 27 years old, found that cannabis use was associated with drug-related offences and alcohol with violent behavior (Pedersen and Skardhamar, 2010; Norström and Pape, 2010). Further results from a meta-analysis (data from 20 different studies and a sample of 18,423 participants) concluded that the risk of violence is relatively high within individuals with psychosis (of both genders) and substance-abuse comorbidity compared with general population controls (Fazel et al., 2009). The history of imprisonment factor can be interpreted by the fact that the use of cannabis may

precipitate or contextualize the use of violence among schizophrenic patients.

Medication non-adherence was found as another important risk factor related to the cannabis use among schizophrenic patients. This result is supported by the findings of a meta-analysis of 11 studies conducted by Foglia *et al.* (2017) in which they found that cannabis use is associated with a nearly 150% increase in the risk of non-adherence for cannabis users as compared to non-users (OR 2.46, CI 1.97–3.07, $p < 0.00001$). Another study conducted by Miller *et al.* (2009) showed that cannabis use increases both the non-adherence to medication treatment for schizophrenia and the dropout of treatment. However, there are some conflicting reports regarding the correlation between cannabis use and non-adherence to medication or treatment dropout. For instance, Linszen *et al.* (1994) showed no differences in non-adherence to medication treatment between users and non-users of cannabis.

Cannabis consumption is not associated with higher severity of psychiatric symptoms

Several studies reported that psychoactive substances can aggravate or precipitate the positive symptoms (delirium, and hallucination) among the majority of schizophrenic patients. However, it seems possible that they alleviate the negative symptoms, particularly anhedonia, social inhibition, or even cognitive failures (Grech *et al.*, 2005).

This study showed no difference in symptoms of schizophrenia between the cannabis users and non-users as they have almost same levels of depression as well as positive and negative symptoms of schizophrenia. This leads to a limitation in the interpretation of the results. The absence of any deference is due to the fact that all the participants, whether they use cannabis or not, were subject to hospitalization and medical treatment. This may be the reason behind the absence of the

differences in psychotic, depressive, or anxious symptoms.

Impulsiveness and cannabis use

Our results showed that in a group of patients with schizophrenia, the mean scores, based on the BIS scale, are higher for users compared to non-users of cannabis. The results of the present study are similar to those from previous studies evaluating impulsivity in a sample of two independent schizophrenic groups with substance abuse disorders (Dervaux *et al.*, 2001; Gut-Fayand *et al.*, 2001). It was not possible to determine the relationship between impulsivity and cannabis use because of the nature of the research (a cross-sectional study).

The reasons why impulsivity could be associated with substance use still need to be clarified. Several interpretation of the relationship between impulsivity and substance abuse are given in the literature. Gut-Fayand *et al.* (2001) suggested that high impulsivity may result in substance use as a maladaptive behavior in response to prodromal symptoms, precipitating the onset of psychosis. However, Liraud and Verdoux, (2000) concluded that the impulsivity might lead to substance abuse in a non-specific manner. Another possible interpretation, which complements the first one, was proposed by Hogarth (2011): impulsivity increases hypersensitivity to drug reinforcement which leads to high rates of drug-seeking/taking. A prospective longitudinal follow-up of a cohort of young subjects, studying the occurrence of impulsivity, sensation seeking, substance abuse, and/or schizophrenia, would be more reliable but hardly feasible.

In this study, no apparent associations between cannabis use and general functioning as well as the number of hospitalization were observed. Despite of these mixed findings, some studies found that people with psychosis who regularly use cannabis suffer from more positive symptoms, more frequent relapses and higher numbers of hospitalization (Grech *et*

Determining factors for cannabis use in schizophrenia

al., 2005; Schoeler et al., 2017). Cannabis use increases the risk of relapse, the number of relapses as well as their length, care intensity index at follow-up, and time until a relapse occurred (Gregg et al., 2007).

Reasons for substance use in people with schizophrenia

Several reasons lead patients with schizophrenia to abuse substances more specifically cannabis. Previous studies demonstrated that schizophrenic patients tend to use substance abuse (or illicit drugs) as a self-medication for tension, low mood, anxiety as well as negative symptoms (Drake, 2008; Lobban et al., 2010; Charles and Weaver, 2010). The first reason is the self-medication hypothesis that has been refuted by several studies (D'Souza et al., 2009; Dubertret et al., 2006; Potvin et al., 2006) and it found lower negative symptom score (e.g. in emotional withdrawal) among cannabis-dependent patients with schizophrenia (Larsen et al., 2006; Arndt et al., 1992). People with psychosis may use cannabis because of its benefits such as reduction of anxiety and increased sociability (Larsen et al., 2006). Another reason that leads patients to consume cannabis is the personality trait. As for non-schizophrenic patients, high levels of impulsivity and sensation seeking, play a role in promoting addictive behaviors in patients with schizophrenia (Gut-Fayand et al., 2001; Liraud and Verdoux, 2000). Also, antisocial personality traits are associated with substance use among patients with schizophrenia (Mueser et al., 1997).

Limitation

Possible limitations of this study included the predominance of the male gender, exclusively hospital recruitment (exclusively inpatients), absence of the long-term longitudinal follow-up of patients, and the point that cannabis metabolites in urine can persist for several weeks. This may lead to false interpretations of the patients' reports as their answers correspond to prior periods

before their hospitalization. Another limitation of the present study is that the sample of patients included is not representative of the general population of the Moroccan schizophrenic patients. Exclusion of patients who are not able to interact with interviewers due to the severity of their psychiatric state, can be considered another limitation.

To our knowledge, this is the first study to confirm the prevalence of cannabis use among schizophrenic patients hospitalized using urine toxicological analysis. The findings of this study indicated that cannabis use is prevalent among hospitalized schizophrenic patients, particularly among young and male patients. This is often associated with medication non-adherence and a history of imprisonment.

Therefore, schizophrenic patients should be sensitized to the negative effects of cannabis in order to make them not using or at least reducing their cannabis use. Hospitalization might provide a possibility to give the required information and treatment for such frequent addictive disorder. More prospective studies are still needed to explain the effects of cannabis consumption and the cannabis use disorders on schizophrenia. Finally, this study reveals the need for local epidemiological and clinical studies on substance or cannabis use disorder in schizophrenia, in order to ensure that therapeutic interventions are targeted more effectively.

Acknowledgment

We would like to thank all the participating researchers (staff members and clinicians) from psychiatric hospital Ibn Al Hassan and the department of toxicology (University Hospital Hassan II of Fes) for their support and collaboration. We would like also to thank all patients for participating in this study.

Conflicts of interest

The authors have declared that there is no conflict of interest.

References

- American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 2003. DSM-IV-TR 2ndéd. Paris: Masson.
- Arndt S, Tyrrell G, Flaum M, Andreasen NC. 1992. Comorbidity of substance abuse and schizophrenia: the role of pre-morbid adjustment. *Psychol Med*, 22: 379-388.
- Bessa MA, Mitsuhiro SS, Chalem E, Barros MM, Guinsburg R, Laranjeira R. 2010. Underreporting of use of cocaine and marijuana during the third trimester of gestation among pregnant adolescents. *Addict Behav*, 35: 266-269.
- Cantor-Graae E, Nordstrom LG, McNeil TF. 2001. Substance abuse in schizophrenia: a review of the literature and a study of correlates in Sweden. *Schizophr Res*, 48: 69-82.
- Carey KB, Carey MP, Chandra PS. 2003. Psychometric evaluation of the alcohol use disorders identification test and short drug abuse screening test with psychiatric patients in India. *J Clin Psychiat*, 64: 767-774.
- Carey KB, Correia CJ. 1998. Severe mental illness and addictions: assessment considerations. *Addict Behav*, 23: 735-748.
- Caspi A, Moffitt TE, Cannon M, McClay J, Murray R, Harrington H, Taylor A, Arseneault L, Williams B, Braithwaite A, Poulton R, Craig IW. 2005. Moderation of the effect of adolescent onset cannabis use on adult psychosis by a functional polymorphism in the catechol O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. *Biol Psychiatry*, 57: 1117-1127.
- Charles V, Weaver T. 2010. A qualitative study of illicit and non-prescribed drug use amongst people with psychotic disorders. *J Ment Health*, 19: 99-106.
- Compton MT, Kelley ME, Ramsay CE, Pringle M, Goulding SM, Esterberg ML, Stewart T, Walker EF. 2009. Association of preonset cannabis, alcohol, and tobacco use with age at onset of prodrome and age at onset of psychosis in first-episode patients. *Am J Psychiatry*, 166: 1251-1257.
- Ddington D, Addington J, Maticka-Tyndale E. 1993. Assessing depression in schizophrenia: the calgary depression scale. *Br J Psychiatry*, 22: 39-44.
- de Beaupaire R, Lukasiewicz M, Beauverie P, Castéra S, Dagherne O, Espaze R, Falissard B, Giroult P, Houery M, Mahuzier G, Matheron I, Niel P, Padovani P, Poisson N, Richier JP, Rocher J, Ruetsch O, Touzeau D, Visinoni A, Molimard R. 2007. Comparison of self-reports and biological measures for alcohol, tobacco, and illicit drugs consumption in psychiatric inpatients. *Eur Psychiatry*, 22: 540-548.
- Degenhardt L, Coffey C, Romaniuk H, Swift W, Carlin JB, Hall WD, Patton GC. 2013. The persistence of the association between adolescent cannabis use and common mental disorders into young adulthood. *Addiction*, 108: 124-133.
- Degenhardt L, Hall W, Lynskey M. 2003. Testing hypotheses about the relationship between cannabis use and psychosis. *Drug Alcohol Depend*, 71 : 37-48
- Dervaux A, Baylé FJ, Laqueille X, Bourdel MC, Le Borgne MH, Olié JP, Krebs MO. 2001. Is substance abuse in schizophrenia related to impulsivity, sensation seeking or anhedonia? *Am J Psychiatry*, 158: 492-494.
- Di Forti M, Iyegbe C, Sallis H, Kolliakou A, Falcone MA, Paparelli A, Sirianni M, La Cascia C, Stilo SA, Marques TR, Handley R, Mondelli V, Dazzan P, Pariante C, David AS, Morgan C, Powell J, Murray RM. 2012. Confirmation that the AKT1 (rs2494732) genotype influences the risk of psychosis in cannabis users. *Biol Psychiatry*, 72: 811-816.
- Di Forti M, Sallis H, Allegri F, Trotta A, Ferraro L, Stilo SA, Marconi A, La Cascia C, Reis Marques T, Pariante C, Dazzan P, Mondelli V, Paparelli A, Kolliakou A, Prata D, Gaughran F, David AS, Morgan C, Stahl D, Khondoker M, MacCabe JH, Murray RM. 2014. Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users. *Schizophr Bull*, 40: 1509-1517.
- Donoghue K, Doody GA, Murray RM, Jones PB, Morgan C, Dazzan P, Hart J, Mazzoncini R, Maccabe JH. 2014. Cannabis use, gender and age of onset of schizophrenia: data from the AESOP study. *Psychiatry Res*, 215: 528-532.
- Drake RE. 2008. Management of substance use disorder in schizophrenia, patients: current guidelines. *CNS Spectr*, 12: 27-32.
- D'Souza DC, Sewell RA, Ranganathan M. 2009. Cannabis and psychosis/schizophrenia: human studies. *Eur Arch Psychiatry Clin Neurosci*, 7: 413-

Determining factors for cannabis use in schizophrenia

- 431.
- Dubertret C, Bidard I, Ades J, Gorwood P. 2006. Lifetime positive symptoms in patients with schizophrenia and cannabis abuse are partially explained by co-morbid addiction. *Schizophr Res*, 86 : 284-290.
- Dugré JR, Dellazizzo L, Giguère C-É, Potvin S, Dumais A. 2017. Persistency of cannabis use predicts violence following acute psychiatric discharge. *Front Psychiatry*, 8: 176.
- El ghazouani F, Aarab C, Lahlou F, Elrhazi K, Aalouane R, Rammouz I. 2015. Substances use among inpatients with relapse of schizophrenia: Cross-sectional study. *Ann Med Psychol*, 6:415-519.
- Fazel S, Gulati G, Linsell L, Geddes JR, Gram M. 2009. Schizophrenia and violence: Systematic review and meta-analysis. *PLoS Med*, 6: e1000120.
- Foglia E, Schoeler T, Klamerus E, Morgan K, Bhattacharyya S. 2017. Cannabis use and adherence to antipsychotic medication: a systematic review and meta-analysis. *Psychol Med*, 10:1691-1705.
- Foti DJ, Kotov R, Guey LT, Bromet EJ. 2010. Cannabis use and the course of schizophrenia: 10-year follow-up after first hospitalization. *Am J Psychiatry*, 167: 987-993.
- Grech A, Van Os J, Jones PB, Lewis SW, Murray RM. 2005. Cannabis use and outcome of recent onset psychosis. *Eur Psychiatry*, 20: 349-353.
- Green B, Young R, Kavanagh D. 2005. Cannabis use and misuse prevalence among people with psychosis. *Br J Psychiatry*, 187: 306-313.
- Gregg L, Barrowclough C, Haddock G. 2007. Reasons for increased substance use in psychosis. *Clin Psycho Rev*, 27 : 494-510.
- Gut-Fayand A, Dervaux A, Olié JP, Lôo H, Poirier MF, Krebs MO. 2001. Substance abuse and suicidality in schizophrenia: a common risk factor linked to impulsivity. *Psychiatry Re*, 102: 65-72.
- Hambrecht M, Hafner H. 1996. Substance abuse and the onset of schizophrenia. *Biol Psychiatry*, 11:1155-1163.
- Helle S, Ringen PA, Melle I, Larsen TK, Gjestad R, Johnsen E, Lagerberg TV, Andreassen OA, Kroken RA, Joa I, Ten VeldenHegelstad W, Løberg EM. 2016. Cannabis use is associated with 3 years earlier onset of schizophrenia spectrum disorder in a naturalistic, multi-site sample (N = 1119). *Schizophr Res*, 170: 217-221.
- Henquet C, Murray R, Linszen D, van Os J. 2005a. The environment and schizophrenia: the role of cannabis use. *Schizophr Bull*, 31: 608-612.
- Henquet C, Krabbendam L, Spauwen J, Kaplan C, Lieb R, Wittchen HU, van Os J. 2005b. Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. *BMJ*, 330: 11-14.
- Hogarth L. 2011. The role of impulsivity in the aetiology of drug dependence: Reward sensitivity versus automaticity. *Psychopharmacology*, 215: 567-580.
- Jimenez-Castro L, Hare E, Medina R, Raventos H, Nicolini H, Mendoza R, Escamilla M. 2010. Substance use disorder comorbidity with schizophrenia in families of Mexican and Central American ancestry. *Schizophr Res*, 120: 87-94.
- Kay SR, Fiszbein A, Opler LA. 1987. The positive and negative syndrome scale (PANSS) for schizophrenia. *Schizophr Bull*, 13: 261-276.
- Kilpatrick B, Howlett M, Sedgwick P, Ghodse AH. 2000. Drug use, self-report and urinalysis. *Drug Alcohol Depend*, 58: 111-116.
- Koskinen J, Löhönen J, Koponen H, Isohanni M, Miettunen J. 2010. Rate of cannabis use disorders in clinical samples of patients with schizophrenia: a meta-analysis. *Schizophr Bull*, 36: 1115-1130.
- Large M, Mullin K, Gupta P, Harris A, Nielssen O. 2014. Systematic meta-analysis of outcomes associated with psychosis and comorbid substance use. *Aust N Z J Psychiatry*, 48: 418-432.
- Large M, Sharma S, Compton MT, Slade T, Nielssen O. 2011. Cannabis use and earlier onset of psychosis: a systematic meta-analysis. *Arch Gen Psychiatry*, 68: 555-561.
- Larsen TK, Melle I, Auestad B, Friis S, Haahr U, Johannessen JO, Opjordsmoen S, Rund BR, Simonsen E, Vaglum P, McGlashan TH. 2006. Substance abuse in first-episode non-affective psychosis. *Schizophr Res*, 88: 55-62.
- Linszen DH, Dingemans PM, Lenior ME. 1994. Cannabis abuse and the course of recent-onset schizophrenic disorders. *Arch Gen Psychiatry*, 4:273-279.
- Liraud F, Verdoux H. 2000. Which temperamental characteristics are associated with substance use in subjects with

- psychotic and mood disorders? *Psychiatry Res*, 93: 63-72.
- Lobban F, Barrowclough C, Jeffery S, Bucci S, Taylor K, Mallinson S, Fitzsimmons M, Marshall M. 2010. Understanding factors influencing substance use in people with recent onset psychosis. *Soc Sci Med*, 70: 1141-1147.
- Marconi A, Di Forti M, Lewis CM, Murray RM, Vassos E. 2016. Meta-analysis of the association between the level of cannabis use and risk of psychosis. *Schizophr Bull*, 42:1262-1269.
- Mieczkowski T. 2010. Urinalysis and hair analysis for illicit drugs of driver applicants and drivers in the trucking industry. *J Forensic Leg Med*, 17: 254-260.
- Miller R, Ream G, McCormack J, Gunduz-Bruce H, Sevy S, Robinson D. 2009. A prospective study of cannabis use as a risk factor for non-adherence and treatment dropout in first-episode schizophrenia. *Schizophr Res*, 113: 138-144.
- Møller T, Linaker OM. 2010. Using brief self-reports and clinician scales to screen for substance use disorders in psychotic patients. *Nord J Psychiatry*, 64: 130-135.
- Mueser KT, Drake RE, Ackerson TH, Alterman AI, Miles KM, Noordsy DL. 1997. Antisocial personality disorder, conduct disorder, and substance abuse in schizophrenia. *J Abnorm Psychol*, 106: 473-477.
- Mustonen A, Niemelä S, Nordström T, Murray GK, Mäki P, Jääskeläinen E, Miettunen J. 2018. Adolescent cannabis use, baseline prodromal symptoms and the risk of psychosis. *Br. J. Psychiatry*, 212: 227-233.
- Norström T, Pape H. 2010. Alcohol, suppressed anger and violence. *Addiction*, 105: 1580-1586.
- Patton JH, Stanford MS, Barratt ES. 1995. Factor structure of the Barratt impulsiveness scale. *J Clin Psychol*, 51: 768-774.
- Pedersen W, Skardhamar T. 2010. Cannabis and crime: findings from a longitudinal study. *Addiction*, 105: 109-118.
- Potvin S, Sepehry AA, Stip E. 2006. A meta-analysis of negative symptoms in dual diagnosis schizophrenia. *Psychol Med*, 36: 431-440.
- Reiger D, Farmer M, Rae D, Locke B, Keith S, Judd L, Goodwin F. 1990. Comorbidity of mental disorders with alcohol and other drug abuse: results from the Epidemiologic Catchment Area (ECA) Study. *JAMA*, 264: 2511-2518.
- Schanda H, Stompe T, Ortwein-Swoboda G. 2010. [Increasing criminality in patients with schizophrenia: fiction, logical consequence or avoidable side effect of the mental health reforms?]. *Neuropsychiatr*, 24: 170-181.
- Schoeler T, Petros N, Bhattacharyya S. 2017. Poor medication adherence and risk of relapse associated with continued cannabis use in patients with first-episode psychosis: a prospective analysis. *Lancet psychiatry*, 4: 627-633.
- Schoeler T, Petros N, Di Forti M, Klamerus E, Foglia E, Ajnakina O, Gayer-Anderson C, Colizzi M, Quattrone D, Behlke I, Shetty S, McGuire P, David AS, Murray R, Bhattacharyya S. 2016. Effects of continuation, frequency, and type of cannabis use on relapse in the first 2 years after onset of psychosis: an observational study. *Lancet Psychiatry*, 3: 947-953.
- Seddon JL, Birchwood M, Copello A, Everard L, Jones PB, Fowler D, Amos T, Freemantle N, Sharma V, Marshall M, Singh SP. 2016. Cannabis use is associated with increased psychotic symptoms and poorer psychosocial functioning in first-episode psychosis: a report from the UK National EDEN study. *Schizophr Bull*, 42: 619-625.
- Thompson K, Kulkarni J, Sergejew AA. 2000. Reliability and validity of a new medication adherence rating scale (MARS) for the psychoses. *Schizophr Res*, 42: 241-247.
- Van Dijk D, Koeter M JW, Hijman R, Kahn RS, van den Brin kW. 2012. Effect of cannabis use on the course of schizophrenia in male patients: a prospective cohort study. *Schizophr Res*, 137: 50-57.
- Volkow ND. 2009. Substance use disorders in schizophrenia clinical implications of comorbidity. *Schizophr Bull*, 35: 469-472.